These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 15025846)

  • 1. Uric acid: role in cardiovascular disease and effects of losartan.
    Alderman M; Aiyer KJ
    Curr Med Res Opin; 2004 Mar; 20(3):369-79. PubMed ID: 15025846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serum uric acid--a cardiovasular risk factor?].
    Alderman M; Redfern JS
    Ther Umsch; 2004 Sep; 61(9):547-52. PubMed ID: 15493113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Uric acid--more deleterious than we thought?].
    Høieggen A; Os I; Kjeldsen SE
    Tidsskr Nor Laegeforen; 2005 May; 125(10):1330-2. PubMed ID: 15909004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uric acid and oxidative stress: relative impact on cardiovascular risk?
    Strazzullo P; Puig JG
    Nutr Metab Cardiovasc Dis; 2007 Jul; 17(6):409-14. PubMed ID: 17643880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
    Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
    J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
    Díez J
    Clin Ther; 2006 Jun; 28(6):832-48. PubMed ID: 16860167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
    de Simone G; Wachtell K; Palmieri V; Hille DA; Beevers G; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Julius S; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Devereux RB
    Circulation; 2005 Apr; 111(15):1924-31. PubMed ID: 15837945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does asymptomatic hyperuricaemia contribute to the development of renal and cardiovascular disease? An old controversy renewed.
    Kanellis J; Feig DI; Johnson RJ
    Nephrology (Carlton); 2004 Dec; 9(6):394-9. PubMed ID: 15663643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Other antihyperuricemic agents].
    Ogino K; Igawa O; Hisatome I
    Nihon Rinsho; 2008 Apr; 66(4):754-7. PubMed ID: 18409527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
    Ibsen H; Lindholm LH; Pedersen OL; Dahlöf B; Kjeldsen S
    Ugeskr Laeger; 2003 Jan; 165(5):459-62. PubMed ID: 12599844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uric acid in hypertension and cardiovascular disease.
    Alderman M
    Can J Cardiol; 1999 Nov; 15 Suppl F():20F-2F. PubMed ID: 10579748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study.
    Chen JH; Chuang SY; Chen HJ; Yeh WT; Pan WH
    Arthritis Rheum; 2009 Feb; 61(2):225-32. PubMed ID: 19177541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B; Gleim G; Panish J
    Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT1 blockers and uric acid metabolism: are there relevant differences?
    Puig JG; Torres R; Ruilope LM
    J Hypertens Suppl; 2002 Jun; 20(5):S29-31. PubMed ID: 12184060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of hyperuricemia in vascular disorders.
    Edwards NL
    Curr Opin Rheumatol; 2009 Mar; 21(2):132-7. PubMed ID: 19339923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.